色情男女在线完整免费_希崎在线观看_熟组词语_泰坦尼克号227分版

A leader in early detection, diagnosis, and intervention of chronic diseases 

Safeguarding Your Well-being from Chronic Diseases

About BioChain

A leader in early detection, diagnosis, and intervention of chronic diseases

Founded in 2006, BioChain (Beijing) Science & Technology, Inc., or BioChain for short, has since become an industry leader in the early detection, diagnosis, and intervention (hereinafter referred to as the “Triple E”) of chronic diseases. The Company diligently works in the prevention of cancer, cardiovascular and cerebrovascular diseases, diabetes, cognitive disorders, and other chronic diseases. BioChain is committed to providing targeted and safe Triple E products and services with higher medication adherence and broader applicability in the early phase of diseases.

BioChain’s blood-based DNA methylation assay kits for both colorectal cancer (CRC) and gastric cancer are the first self-developed DNA methylation diagnostic products approved by the National Medical Products Administration (NMPA) in China. In addition, they have been applied in hundreds of top-tier hospitals and incorporated into the medical insurance system in many parts of the country. The Company has an impressive pipeline of proprietary products, including the point-of-care monitoring (POCM) series, early diagnostic tools for esophageal, liver, and lung cancers, respectively. It also has a multi-cancer NGS screening platform. Furthermore, BioChain is committed to developing initiatives to diagnose and treat stroke and other cardiovascular and cerebrovascular diseases at an early stage. With the goal of “Safeguarding Your Well-being from Chronic Diseases,” BioChain will continue to refine and expand its “Triple E” applications.

 View More  

Technological Innovations

The leading innovator in the “Triple E*” approach to chronic diseases

The World’s First

The world’s first blood-based DNA methylation assay kit for the early diagnosis of CRC to be approved by the authoritative FDA (U.S.), NMPA (China), and CE marking (Europe), filling the gap at home and abroad.

The World’s Only

The world’s only DNA methylation assay kit for the early diagnosis of gastric cancer, approved by the NMPA in China.

China’s First

The first NMPA-approved DNA methylation assay kit for the early diagnosis of colorectal cancer in China.

China’s First

The first DNA methylation assay kits for early diagnosis of CRC and gastric cancer in China which have been incorporated into the medical insurance system.

China’s Only

The only company in China to receive two NMPA approvals for innovative medical devices in the field of early cancer diagnosis based on DNA methylation.

Successively selected

Consistently chosen for the China National Key R&D Program during the 13th and 14th Five-Year Plan periods.

World’s Largest

Partnered with Beijing Tiantan Hospital to establish the first Epigenetics Research Joint Laboratory in China. It also participated in the world’s largest cohort study of cerebrovascular accidents (or strokes) in epigenetic studies, involving more than 10,000 participants.

Product System

Comprehensive solutions for the “Triple E*” approach to chronic diseases.

Cancer

 View More  

Other Chronic Diseases

 View More  

Infectious Diseases

 View More  

Others

 View More  

Authoritative Certifications

Dedicated to developing excellent products and services for the “Triple E*” approach to chronic diseases

At BioChain, we always prioritize the needs of the customer. We have established a comprehensive system for product registration, production management, and quality control that is highly efficient, pragmatic, and fully regulatory-compliant. Every aspect of our operations, from R&D to registration, procurement, production, sales, logistics, and clinical testing services, adheres strictly to quality regulations and standard operating procedures. This approach provides a solid foundation for the development of exceptional products and services that meet the highest standards of excellence.

Product Registration Certificate

NMPA (the National Medical Products Administration, China) Approval

• Dozens of proprietary products have obtained NMPA approval
• Both DNA methylation test kits for the early diagnosis of colorectal cancer (思博定®) and gastric cancer (思博衛®) were the first self-developed diagnostic products approved by the NMPA for innovative Class III medical devices

CE Approval

• By 2023, BioChain has received CE marking for a total of 49 proprietary products, including the early cancer detection and diagnostic series, the Point-of-Care Monitoring (POCM) series, and the Novel Coronavirus antibody detection series

Quality Control Certifications 

ISO (International Organization for Standardization) Certification

• Acquired ISO13485 certification, the international standard for quality assurance of medical devices

NCCL (National Center for Clinical Laboratories, China) Certification

• From 2015 to 2022, BioChain’s wholly-owned Medical Laboratory acquired the NCCL external quality assessment (EQA) certificate with full scores for 8 consecutive years

色情男女在线完整免费 国产特黄1级毛片| 欧美黄色片网址| 男人和女人性配过程视频| 91在线视频观看| 午夜dy888| 我在厨房摸岳的乳| 国产成人91激情在线播放| 市来美保在线观看| 撅起来调教屁股狠打男男| 91视频欧美| 网曝门在线| 性爱交叉点| 亚洲国产精品久久久久| 235欧美理论电影在线观看| 黄色片一区| 亚洲国产精品婷婷久久久久| 5一级潘金莲大片| 耽美多肉文| 超91在线| 老女人一级片| 国产第1页| 调教放荡公用便器男男| 成人午夜久久精品| 日本邪恶帝| 大胸美女挤奶| 国产精品第7页| 操处女逼视频| 意大利xxxx性hd极品| 男男互操小说| 九九精品在线播放| 最新福利在线| 硕大的双乳警花蹂躏| 极品外围| 武则天毛片| 国产亚洲精品2021自在线| 草逼视频网站| 国产私拍在线| 波多野结衣三级在线| 国产福利在线免费| 欧美老少欢交另类| 久久91精品国产91久久| http://www.summerscholars.org http://www.josephinefurnishings.com http://www.juanmail.com http://www.91porn.desi http://www.tonerverkauf.com http://www.mauisurfphotography.com